Eleusis SPAC

Introducing Andala-Managed Clinics¹ Opportunity TAM (US) Business Model Core Competency Launch Therapy Address the "last mile" challenge of psychedelic drug therapy $7bn¹ (estimate assumes FDA approved psychedelic drug therapy for MDD, PTSD, and substance abuse) In-network high-throughput specialty psychiatric drug therapy Operational integration with existing healthcare infrastructure SPRAVATO (esketamine) (Indications: TRD, MDD w/Acute Suicidality) (♡♡♡♡ andala 1st Anticipated Milestone Prototype Launch 1H 2022 ✓ In-network Payor Model ✓ Targeting 3 Prototype Managed Clinics 2nd Anticipated Milestone Commercial Proof-of-Concept 2H 2022 2023 ✓Prototype Managed Clinics Achieve Cash Flow Positive Operations ✓ National Expansion Notes and Sources: 1) Eleusis expects to divest Andala in advance of FDA approval of ELE-Psilo or any other drug candidate and may elect to divest in whole or in part in advance of FDA approval. 2) Partheniou, A. (2021) Psychedelics - A possible disrupter to legacy treatments, Stifel Nicholaus Canada Inc, 01/14/2021 (estimate based in part on data from existing ketamine clinics). 25

View entire presentation